First Trust Exchange-Traded Fund. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT | 5.60% | $157.46M | 1,810,937 |
| NEOGENOMICS INCNEO | 5.12% | $144.00M | 9,869,496 |
| VERACYTE INCVCYT | 5.10% | $143.37M | 2,441,185 |
| BRUKER CORPBRKR | 4.32% | $121.51M | 2,019,057 |
| ALKERMES PLC | 4.24% | $119.20M | 2,275,074 |
| ILLUMINA INCILMN | 3.92% | $110.35M | 627,605 |
| KRYSTAL BIOTECH INCKRYS | 3.87% | $108.91M | 293,036 |
| NATERA INCNTRA | 3.79% | $106.73M | 393,185 |
| AXSOME THERAPEUTICS INCAXSM | 3.71% | $104.30M | 426,122 |
| NEUROCRINE BIOSCIENCES INCNBIX | 3.53% | $99.24M | 588,847 |
| BIO-TECHNE CORPTECH | 3.43% | $96.54M | 1,366,518 |
| ARROWHEAD PHARMACEUTICALS INCARWR | 3.38% | $94.97M | 1,165,127 |
| BIOGEN INCBIIB | 3.37% | $94.80M | 438,784 |
| EXELIXIS INCEXEL | 3.32% | $93.28M | 1,714,400 |
| INCYTE CORPINCY | 3.18% | $89.56M | 790,013 |
| ARGENX SEARGX | 3.13% | $88.06M | 94,913 |
| HALOZYME THERAPEUTICS INCHALO | 3.11% | $87.59M | 1,119,086 |
| VERTEX PHARMACEUTICALS INCVRTX | 3.07% | $86.42M | 173,968 |
| REPLIGEN CORPRGEN | 3.07% | $86.22M | 631,943 |
| BIOMARIN PHARMACEUTICAL INCBMRN | 2.83% | $79.64M | 1,391,830 |
| AMGEN INCAMGN | 2.78% | $78.30M | 216,227 |
| BIONTECH SEBNTX | 2.63% | $73.95M | 794,727 |
| GENMAB A/SGMAB | 2.62% | $73.80M | 2,686,600 |
| UNITED THERAPEUTICS CORPUTHR | 2.56% | $71.93M | 132,748 |
| ALNYLAM PHARMACEUTICALS INCALNY | 2.52% | $70.92M | 235,602 |
| BEONE MEDICINES LTDONC | 2.48% | $69.84M | 245,095 |
| GILEAD SCIENCES INCGILD | 2.45% | $68.97M | 545,899 |
| ADMA BIOLOGICS INCADMA | 2.33% | $65.48M | 7,823,567 |
| SAREPTA THERAPEUTICS INCSRPT | 2.29% | $64.39M | 3,583,400 |
| REGENERON PHARMACEUTICALS INCREGN | 2.25% | $63.20M | 101,350 |
| DREYFUS GOVERNMENT CASH MANAGEMENT FUNDSCash or money market | 0.05% | $1.53M | 1,526,391 |
| DAIWA CAPITAL MARKETS AMERICA INC.RA | 0.00% | $4.69K | 4,689 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.